Axonics Modulation Technologies

Axonics Modulation Technologies is a United States medical technology company based in Irvine, California. The company developed implantable sacral neuromodulation (SNM) systems for people with certain urinary and bowel control disorders. Its devices deliver electrical stimulation to the sacral nerves, with the aim of helping manage symptoms. The company’s product family has included implantable neurostimulators, patient controls and accessories, as well as systems and equipment used during evaluation or implantation. Axonics was established in 2012 and built its business around developing an alternative to existing sacral neuromodulation therapies. Its offerings have included rechargeable and recharge-free implantable systems. The company also expanded into a related urology treatment area through Bulkamid, a urethral bulking product used for stress urinary incontinence, which it acquired in 2021. Its products are intended for use by healthcare professionals and patients in specialist care settings; they are medical devices rather than general consumer products. Axonics became a publicly traded company on Nasdaq under the ticker AXNX. Boston Scientific agreed to acquire the company in 2024, and completed the acquisition that year. Axonics is consequently part of Boston Scientific, a global medical technology company. Boston Scientific describes its broader work as developing minimally invasive technologies and medical solutions. Axonics’ brand and product portfolio are associated particularly with neuromodulation and urology, while ownership and corporate oversight sit within Boston Scientific.

Axonics Modulation Technologies was founded in 2012 and established its base in Irvine, California. It entered medical technology with a focus on sacral neuromodulation, a treatment approach that uses electrical stimulation of sacral nerves to help manage symptoms associated with certain urinary and bowel control disorders. The company developed implantable systems and associated patient and clinical-use components, positioning itself as a specialist alternative in the neuromodulation field. The company’s product development included rechargeable and recharge-free implantable neurostimulator options. Its system portfolio also involved components used in patient control and in the evaluation and delivery of therapy. Axonics’ commercial activity centered on specialist healthcare settings, where device selection, implantation, programming and ongoing management involve healthcare professionals. Axonics expanded beyond its core neuromodulation portfolio in 2021 by acquiring Bulkamid, a urethral bulking product used for stress urinary incontinence. This broadened the company’s presence in urology while keeping its offerings within treatment areas related to urinary conditions. Axonics subsequently operated as a publicly traded company on Nasdaq under the symbol AXNX. In 2024, Boston Scientific agreed to acquire Axonics and completed the transaction that year. The acquisition brought Axonics into Boston Scientific’s medical technology business. Boston Scientific’s supplied corporate materials describe its broader mission as developing minimally invasive technologies and medical solutions. Following the transaction, Axonics is best understood as a medical technology business and product portfolio within Boston Scientific rather than as an independent listed company. The supplied evidence identifies Axonics as a company in Irvine, United States, while Boston Scientific’s official pages provide corporate context but do not themselves detail Axonics’ products or acquisition history.

• 2024

  Acquired by Boston Scientific

• 2021

  Bulkamid acquisition

• 2019

  U.S. clearance for its sacral neuromodulation system

• 2012

  Axonics is founded

A specialist medical-device company focused on sacral neuromodulation and urology therapies, with products designed for clinical use and patient management.

• Axonics Sacral Neuromodulation System

  An implantable system designed to deliver sacral nerve stimulation for selected urinary and bowel control conditions.

• Bulkamid

  A urethral bulking product used in the treatment of stress urinary incontinence.

• 2024

  Acquisition by Boston ScientificOther

1. 1Advancing Science for Life - US - Boston Scientificbostonscientific.com
2. 2About Us - Our Mission And Values - Boston Scientificbostonscientific.com
3. 3Products for Healthcare Professionals - Boston Scientificbostonscientific.com
4. 4Axonics Modulation Technologies (United States)wikidata.org
5. 5Axonics official websiteaxonics.com